Revvity (RVTY) Operating Income by Segment

Shows operating profit produced by each business unit, revealing which segments generate healthy margins and which absorb cash. Large margin gaps point to differences in pricing power, cost structure, or capital intensity, which matters for where management should prioritize investment or cost controls.

Diagnostics has re-emerged as Revvity’s primary profit engine—operating income recovered from the post‑2021 compression and is trending upward, fueled by instrument orders and stronger immuno/genomics demand. Life Sciences contributes meaningfully but is choppy: core solutions are steady while Signals software drove a recent pullback and remains the key swing factor for margin upside if H2 recovery holds. Corporate overhead has narrowed, helping margins, but part of the recent beat was one‑time (tariff refunds/tax timing), so watch software recovery and production timing for sustainable earnings.